Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

Table 6

Multivariable Cox regression models.

(a) Multivariable Cox regression models in HER2-positive patients since 2006

Characteristic	Overall survival (𝑛=516, events = 53)
	HR	95% CI	𝑃 value
Trastuzumab + CHT + AHT; (𝑛=180, events = 4)	Reference	—	—
CHT + AHT; (𝑛=35, events = 2)	2.34	0.43; 13.38	0.32
Trastuzumab + CHT; (𝑛=91, events = 6)	3.80	0.87; 16.59	0.08
AHT; (𝑛=106, events = 17)	4.28	1.30; 14.05	0.017
CHT; (𝑛=24, events = 3)	9.50	1.90; 47.43	0.006
No adjuvant therapy; (𝑛=80, events = 21)	10.44	3.02; 36.06	<0.001

Model is controlled for age, Ki67 categories, tumor size, nodal status, grading, and receptor status; HR: hazard ratio; 95% CI: 95% confidence interval.

(b) Multivariable Cox regression model in HER2-negative patients since 2006

Characteristic	Overall survival (𝑛=2727, events = 219)
	HR	95% CI	𝑃 value
CHT + AHT; (𝑛=671, events = 23)	Reference	—	—
AHT; (𝑛=1392, events = 104)	2.33	1.40; 3.87	0.001
CHT; (𝑛=279, events = 28)	3.15	1.61; 6.16	0.001
No adjuvant therapy; (𝑛=385, events = 64)	4.91	2.81; 8.59	<0.001

Model is controlled for age, Ki67 categories, tumor size, nodal status, grading, and receptor status; HR: hazard ratio; 95% CI: 95% confidence interval.